# Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

> **NCT07171827** · NA · COMPLETED · sponsor: **Helwan University** · enrollment: 60 (actual)

## Conditions studied

- Anti-CD30
- Brentuximab
- Doxorubicin
- Vinblastine
- Dacarbazine
- Frontline
- Advanced Classical Hodgkin Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin + Doxorubicin, Vinblastine, and Dacarbazine
- **DRUG:** Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine

## Key facts

- **NCT ID:** NCT07171827
- **Lead sponsor:** Helwan University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-01
- **Primary completion:** 2025-02-01
- **Final completion:** 2025-02-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07171827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07171827, "Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07171827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*